Status:
COMPLETED
A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients
Lead Sponsor:
Forest Laboratories
Conditions:
Hypertension
Eligibility:
All Genders
18-79 years
Phase:
PHASE3
Brief Summary
The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses. Its purpose is to study the mechanism of actio...
Eligibility Criteria
Inclusion
- Male or female, ambulatory outpatients 18-79 years old at screening
- Minimum 2-year history of Stage I/II hypertension
- Qualifying blood pressure criteria for study entry and for randomization
- Willing to adhere to the dietary compliance and undergo protocol procedures
- Have a lifestyle that will permit him/her to attend all evaluations, including those conducted on consecutive days
Exclusion
- Have any form of secondary hypertension
- Have clinically significant respiratory or cardiovascular disease
- Presence/history of coronary artery disease or peripheral vascular disease
- Have diabetes mellitus, Type I or II
- Have a history of hypersensitivity to nebivolol, metoprolol, or any beta-blocker
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00648895
Start Date
November 1 2007
Last Update
September 20 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Forest Investigative Site
Houston, Texas, United States, 77030